+

US20060019884A1 - Peptide composition - Google Patents

Peptide composition Download PDF

Info

Publication number
US20060019884A1
US20060019884A1 US10/512,512 US51251205A US2006019884A1 US 20060019884 A1 US20060019884 A1 US 20060019884A1 US 51251205 A US51251205 A US 51251205A US 2006019884 A1 US2006019884 A1 US 2006019884A1
Authority
US
United States
Prior art keywords
peptide
lys
seq
use according
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/512,512
Inventor
John Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pepsyn Ltd
Original Assignee
Pepsyn Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepsyn Ltd filed Critical Pepsyn Ltd
Assigned to PEPSYN LIMITED reassignment PEPSYN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SMITH, JOHN ARTHUR
Publication of US20060019884A1 publication Critical patent/US20060019884A1/en
Priority to US11/502,345 priority Critical patent/US7786081B2/en
Assigned to PEPSYN LTD. reassignment PEPSYN LTD. CHANGE OF ADDRESS Assignors: PEPSYN LIMITED
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Definitions

  • the present invention relates to a protein, a peptide (generally a polypeptide), a peptide derivative, or peptide fragment which can be used to alleviate or prevent an effect-of aging, particularly an effect of aging in skin, by stimulating the production of fibrillin in fibroblasts.
  • This may be in a method of treatment or a cosmetic method.
  • the invention also relates to the same peptides, polypeptides, peptide derivatives or peptide fragments which can be used as a prophylactic or treatment for periodontal diseases (gum diseases) by stimulating the production of fibrillin in fibroblasts. This may be in a medical method of treatment if desired.
  • the invention relates to use of a peptide which comprises an amino acid sequence from an ⁇ -S2 casein precursor.
  • EGF epidermal growth factor
  • IGF insulin-like growth factor
  • II Francis et al., 1986
  • BCGF bovine colostrum growth factor
  • PDGF Platelet-derived Growth Factor
  • bovine milk contains growth promoting activity for a rat mammary fibroblast cell line (Rama 27), which is not significantly stimulated by IGF or PDGF.
  • peptide sequences are identified which elicit this growth promoting activity. These sequences are identified as sequences that are substantially identical to the C-terminal end of bovine ⁇ -S2 casein precursor. The application indicates that these peptides or salts thereof may be used for the manufacture of medicaments or foodstuffs for promoting growth.
  • compositions for treating periodontal disease and signs of aging in skin employs an a-S2 casein precursor capable of stimulating the production of collagen in fibroblasts.
  • an ⁇ -S2 casein precursor and related species such as those disclosed as growth promoters in WO 97/16460, are extremely useful in alleviating and preventing the effects of aging in skin, and in treating periodontal disease, by stimulating the production of fibrillin in fibroblasts.
  • the ⁇ -S2 casein precursor and precursor fragments and derivatives used in the present invention are superior to known anti-aging products and products used for treating gum disease, and in particular to the agents disclosed in the above prior art.
  • the present invention provides use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an ⁇ -S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full ⁇ -S2 casein precursor.
  • the invention also provides use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide has an ⁇ -S2 casein fragment activity.
  • the medicament is effective in alleviating or preventing periodontal disease and/or in alleviating or preventing an effect of aging in skin, preferably an effect of photoaging (damage or aging caused by exposure or overexposure to UV light or sunlight).
  • the above-defined uses of the present invention include use of the peptide, or its derivative, either in a pure form, or in a partially purified form, such as that obtainable by isolation of the peptide from a natural source.
  • the present use may extend to employment of the peptide in its natural unpurified form, such as using a natural substance that comprises the peptide or its derivative, or may involve use of the peptide or its derivative in any level of purification, including entirely (100%) pure.
  • the peptide may also be from a proteolytic digest or a non-natural source, such as a synthetic peptide.
  • the term peptide is intended to include proteins, polypeptides and peptide fragments.
  • the present invention may be employed in a cosmetic and/or medicinal method for alleviating or preventing an effect of aging in skin, which method comprises treating a subject with a polypeptide, or a derivative of a polypeptide, wherein the polypeptide comprises an amino acid sequence present in an ⁇ -S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising the N-terminus of the full ⁇ -S2 casein precursor.
  • a peptide comprising an amino acid sequence from an ⁇ -S2 casein precursor has a very beneficial effect upon the skin, preventing and alleviating many effects of aging, and treating and preventing periodontal disease.
  • the effect of these particular agents is superior to the effect of prior art agents.
  • fragments in the context of the present invention it is meant any part of a sequence from a protein, polypeptide or peptide that is not the full sequence.
  • FIG. 1 shows the result of a cation exchange column chromatography experiment carried out on a dialysed cheese whey salt-cut
  • FIG. 2 shows the results of a hydrophobic interaction column chromatography experiment performed on active fractions from cation exchange chromatography
  • FIG. 3 shows fibrillin production in ten human volunteers treated with peptides of the present invention, compared with occluded controls;
  • FIG. 4 shows a corresponding pooled analysis of this study.
  • the effect of aging may be any effect of aging.
  • the effect may be sagging of the skin, wrinkling of the skin or slow regeneration of damaged areas of skin.
  • the effect is most preferably wrinkling of the skin.
  • the periodontal disease is a disease of the gums. In the context of the present invention, this may be a gum disease arising for any reason, including infection of the teeth or gums as well as lack of cleaning (brushing or flossing) of the teeth or gums.
  • polypeptide and polypeptide fragments used in the present invention may have either an alleviating effect, or a preventative effect, or both. Thus, they may have a prophylactic effect and/or may reduce the effects of gum disease or of aging, or provide protection against the onset of gum disease or may increase the youthful appearance of the skin.
  • ⁇ -S2 casein precursor shows no significant efficacy against the effects of aging or gum disease
  • fragments of such proteins such as polypeptides derived from the C-terminal end of ⁇ -S2 caseins
  • the efficacy against gum disease and effects of aging is present in peptides which are derived from the C-terminal end of ⁇ -S2 casein precursors and have 3 or more amino acids, but do not comprise the N-terminal amino acid of the full ⁇ -S2 casein molecule.
  • the casein-derived peptides and fragments used in the present invention generally comprise 3 or more amino acids and do not comprise the N-terminus of the full casein protein.
  • the peptide not comprising the N-terminal amino acid means that the peptide does not comprise the N-terminal end (N-terminus) of the protein itself. In some embodiments this can mean that the peptide does not comprise a number of amino acids up to and including the N-terminus. Preferably the peptides do comprise the C-terminus of the-full protein.
  • the number of amino acids in the peptide or fragment used the present invention is not especially limited, provided that it has 3 or more amino acids, but does not comprise the N-terminal end of the full casein.
  • the number of amino acids in the peptide is from 3-50, 4-50, 5-50, 6-50, or 7-50.
  • the number of amino acids may be from 8-50 and more preferably from 9-50 or 10-50. It is particularly preferred that the upper limit on the amino acids in all these cases is 35 and most preferably 31. The most preferred number of amino acids is from 9-31.
  • the peptide may preferably comprise the last 3-50, 3-35 or 3-31 amino acids of the C-terminal end of the ⁇ -S2 casein precursor (including the C-terminus) and may even be as short as the last 3-10, 3-9,3-8 or 3-7 or even just the last 3 amino acids of the C-terminal end of the ⁇ -S2 casein.
  • bovine ⁇ -S2 casein precursor used in the present invention has the following amino acid sequence:
  • the peptide comprises an amino acid sequence selected from the following sequences: LysValIleProTyrValArgTyrLeu; ThrLysValIleProTyrValArgTyrLeu; LysThrLysValIleProTyrValArgTyrLeu; ProLysThrLysValIleProTyrValArgTyrLeu; GlnProLysThrLysValIleProTyrValArgTyrLeu; AlaMetLysProTrpIleGlnProLysThrLysValIleProTyrVal ArgTyrLeu; ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys ThrLysValIleProTyrValArgTyrLeu; and ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysPro
  • the polypeptide comprises a bovine ⁇ -S2 casein fragment comprising the sequence LysValIleProTyrValArgTyrLeu.
  • Other particularly preferred sequences referred to above include the last 10, 11, 12 and 13 amino acids of the C-terminal end of the bovine ⁇ -S2 casein precursor. These amino acids are also the same as the last 7 amino acids of the goat and sheep ⁇ -S2 casein precursors, confirming the degree of similarity between these proteins, particularly at their C-termini
  • the peptide comprises an amino acid sequence from the C-terminal end of the bovine ⁇ -S2 casein precursor, but without the last four C-terminal amino acids (i.e. without ValArgTyrLeu).
  • the following sequences are also preferred: LysValIleProTyr; ThrLysValIleProTyr; LysThrLysValIleProTyr; ProLysThrLysValIleProTyr; GlnProLysThrLysValIleProTyr; AlaMetLysProTrpIleGlnProLysThrLysValIleProTyr; ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys ThrLysValIleProTyr; and ProGlnTyrLeuLysThrValTyrGlnHisGlnLysA
  • leucine isoleucine and valine may be interchanged.
  • tyrosine and phenylalanine may also be interchanged, as may arginine and lysine.
  • the invention preferably relates to ⁇ -S2 casein precursor fragments, and more preferably to the peptides referred to in WO 97/16460, for use as a cosmetic product, preferably in a cream or lotion, for reducing an aging effect in skin, such as wrinkles.
  • the invention is preferably applicable to human skin, but may if desired be applied to other skin such as mammalian skin generally.
  • the invention also relates to the ⁇ -S2 casein precursor fragments mentioned above for use as a prophylactic agent or treatment agent for periodontal disease.
  • This preferably relates to such diseases in humans, but may also apply to such diseases in mammalian gums generally if desired.
  • the agent may be in any suitable form, such as a topical agent (e.g. a toothpaste for cleaning the teeth and/or gums) or a chewing gum.
  • the peptides may be used as a pure product, or may conveniently be supplied as an enriched natural preparation from milk by following the protocols described in WO 97/16460 as far as (and including) the hydrophobic interaction chromatography step.
  • cheese whey may be used in place of the acid (milk) whey.
  • the peptides may be used alone, or in combination with acceptable (in some cases pharmaceutically acceptable) additives and/or excipients useful for formulating topical compositions, toothpastes, or chewing gums.
  • Additives for topical agents may include, for example, moisturising agents and/or other agents beneficial to the skin, such as all or any of vitamins A, C, D and E, that are used to beneficial effect to prevent/reverse the aging of skin.
  • the basis of the invention is that the peptides stimulate the production of fibrillin in fibroblasts, especially dermal fibroblasts. This is believed to ameliorate the fibrillin-rich microfibrillar network proximal to the dermal-epidermal junction of aged skin.
  • the peptides are capable of repairing the fibrillin deficit in aged (especially photoaged) skin.
  • the peptides used in the present invention appear to fulfil the equivalent role in bovine milk that EGF does in other species.
  • the present inventors have surprisingly discovered that these peptides are effective as anti-periodontal disease agents and anti-aging agents and are more effective than known products.
  • a further advantage of the peptides used in the present invention is that whilst they have an efficacy similar to, or are superior to, EGF they are regarded as being ‘natural products’ (being milk-derived) and because they have essentially no full protein content, they are not allergenic.
  • the peptide, or derivative of the peptide can be used in the manufacture of a medicament effective in alleviating or preventing an effect of aging in ski, wherein the peptide has an ⁇ -S2 casein fragment activity.
  • the peptide may be an ⁇ -S2 casein precursor fragment, as described in detail above, or ca be a related molecule having a similar activity, such as a homologue.
  • the peptides are particularly effective against photoaging.
  • photoaging of skin means the effects of cumulative exposure to ultra-violet radiation and/or sunlight, or alternatively the combination of chronological ageing and the effects of cumulative exposure to ultra-violet radiation and/or sunlight.
  • the glycoprotein fibrillin may be important. Fibrillin is a major constituent of the elastin network in the papillary dermis and plays an important role in maintaining the integrity of the basement membrane zone.
  • the present invention relates to methods of repairing the basement membrane zone, by stimulating the production of fibrillin.
  • the peptide, or derivative of the peptide can be used in the manufacture of a medicament effective in alleviating or preventing periodontal disease, wherein the peptide has an ⁇ -S2 casein fragment activity.
  • the peptide may be an ⁇ -S2 casein precursor fragment, as described in detail above, or can be a related molecule having a similar activity, such as a homologue.
  • the peptide used in the present invention is capable of stimulating the growth of fibroblasts. It is also preferred that the peptide is capable of stimulating fibroblasts to produce collagen. It is further preferred that the peptide is capable of stimulating growth in keratinocytes.
  • the present invention provides a cosmetic method, or a medical method, for alleviating or preventing an effect of aging in skin by stimulating the production of fibrillin in fibroblasts, which method comprises treating a subject with a peptide, wherein the peptide comprises an amino acid sequence present in an ⁇ -S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full ⁇ -S2 casein precursor.
  • the peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an ⁇ -S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • the present invention provides a topical composition for stimulating the production of fibrillin by fibroblasts, comprising a peptide, or a derivative of a peptide, wherein the peptide comprises an amino acid sequence present in an x-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full ⁇ -S2 casein precursor.
  • the peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an ⁇ -S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • the invention provides a pharmaceutical composition for alleviating or preventing periodontal disease by stimulating the production of fibrillin by fibroblasts, comprising a peptide, or a derivative of a peptide, wherein the peptide comprises an amino acid sequence present in an ⁇ -S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full ⁇ -S2 casein precursor.
  • the peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an ⁇ -S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • This procedure covers the methods for the collection, preparation and storage of Standardised Natural Product (SNP) from cheese whey. Typically, this procedure is used for small-scale preparation of SNP, such as for research and development purposes. However, the procedure can be scaled up as desired for commercial production according to known techniques.
  • SNP Standardised Natural Product
  • Whey was either refrigerated for processing the following day or the whey was frozen at ⁇ 20° C. in shallow 21 containers until required.
  • Frozen whey was thawed by placing a 2 l block of whey in a plastic bag and immersing it in hot running water. Thawing was completed in less than 10 mins and the temperature of the melting whey was maintained below 10° C.
  • the pH of the whey was adjusted to 3.0 using concentrated HCl.
  • 220 g of (NH4) 2 SO 4 (BDH, AnalaR grade) was slowly added over a period of 30 mins whilst stirring. It was left to equilibrate for a further 1 hr 30 mins without stirring, and then centrifuged at 9000 rpm for 40 mins using a SorvallRC-5B centrifuge and associated GS-3 rotor (DuPont Instruments), which were pre-equilibrated to an operating temperature of between 4 and 10° C.
  • Dialysed cheese whey salt-cut was run on cation-exchange chromatography, at 4° C. with a mobile phase of 20 mM sodium phosphate buffer, pH 6.0. Protein was eluted using a linear salt gradient of 100 to 700 mM NaCl provided by a gradient mixer (Pharmacia gradient mixer GM-1). The progress of the run was monitored at 280 nm using a UV monitor (Uvicord S II, Pharmacia).
  • a cation exchange column (Pharmacia XK50series, 50 mm i.d.) was prepared with CM52 carboxymethyl (Whatman) to a packed bed height of 15 cm. This was equilibrated with 500 ml of buffer solution. Dialysed cheese whey salt cut (400 ml) was loaded on the column at a flow rate of 2.5 ml/min and then washed overnight with 500 ml of 50 mM NaCl in buffer at a flow rate of about 0.5 ml/min. A 500 ml linear gradient of 100 to 700 mM NaCl in buffer was applied at a 2.0 ml/min and fractions were collected every 25 ml and numbered sequentially.
  • HIC hydrophobic interaction chromatography
  • a HIC column (Pharmacia C series, 26 mm i.d.) was prepared with Butyl Sepharose 4 Fast Flow (Pharmacia) to give a packed bed height of 15 cm. The column was equilibrated overnight with 250 ml of 4 M NaCl in buffer at a flow rate of 0.25 ml/min.
  • the active fractions from several cation exchange chromatography runs were pooled together to give between 100 and 200 ml of sample.
  • the means concentration of NaCl in this sample was calculated from the estimated concentrations of NaCl in the constituent fractions (Table 1). Solid NaCl was then slowly added to the sample to make it 3.7 M, and the pH was adjusted to 6.5. Sample was loaded on the column added to 2.0 ml/min. A 500 ml eluting gradient of 4 M to 0 M NaCl was applied and fractions were collected every 25 ml and numbered sequentially. The column was then washed with 250 ml of buffer followed by 250 ml of water.
  • This Example shows that the peptides employed in the present invention stimulate the replacement of fibrillin in vivo, aiding in the repair of skin that has been photoaged.
  • the peptides thus have clinical efficacy.
  • Frozen sections were prepared at a thickness of 10 ⁇ m (OTF cryostat, Bright Instruments Ltd.). Three sections per area per patient were treated as follows to identify the fibrillin-rich microfibrillar network by light microscopy:
  • Sections were fixed with 4 vol. % paraformaldehyde in phosphate-buffered saline (10 mins). Following hydration in tris-buffered saline (TBS; 100 mM Tris, 150 mM NaCl), sections were solubilised by addition of 0.5 vol. % Triton-X 100® (10 mins). Following washing, endogenous peroxidase activity was abolished by incubation with an excess of hydrogen peroxide in methanol (30 mins). All sections were then blocked with 1 vol. % normal horse serum+1 vol.
  • % bovine serum albumen prior to application of primary antibody (mouse anti-human fibrillin-1, clone 11C1.3; NeoMarkers, Calif., USA) at a dilution of 1:100.
  • Negative controls were concurrently incubated with either block alone or control mouse serum at a dilution of 1:100.
  • sections were stringently washed with TBS prior to application of the horse anti-mouse IgG biotinylated secondary antibody. This was further conjugated to the enzyme horseradish peroxidase using a commercially available kit following the manufacturers instructions (ABC Elite System, Vector Laboratory, Peterborough UK).
  • Antibody was localised using 3′,3′-diaminobenzadine as chromogen (10 mins incubation). Washing in TBS quenched this reaction. Sections were counterstained using nuclear fast red and finally dehydrated through serial alcohols, cleared and permanently mounted.
  • a known agent for stimulating fibrillin production is all-trans retinoic acid (RA).
  • RA all-trans retinoic acid
  • a drawback of this agent is that it produces marked erythema at the site of application. None of the above subjects produced erythema following application of casein, showing the advantage of this agent over all-trans retinoic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminal amino acid of the full α-S2 casein precursor. Further provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide has an α-S2 casein fragment activity.

Description

  • The present invention relates to a protein, a peptide (generally a polypeptide), a peptide derivative, or peptide fragment which can be used to alleviate or prevent an effect-of aging, particularly an effect of aging in skin, by stimulating the production of fibrillin in fibroblasts. This may be in a method of treatment or a cosmetic method. The invention also relates to the same peptides, polypeptides, peptide derivatives or peptide fragments which can be used as a prophylactic or treatment for periodontal diseases (gum diseases) by stimulating the production of fibrillin in fibroblasts. This may be in a medical method of treatment if desired. In particular the invention relates to use of a peptide which comprises an amino acid sequence from an α-S2 casein precursor.
  • For many years it has been known that, in addition to its nutritional content, milk contains growth promoting activity for cells. In this connection, epidermal growth factor (FGF) has been identified in human (Shing and Klagsbrun, 1984; Petrides, 1985), rat (Raaberg et al., 1990), swine (Tan et al., 1990) and goat (Brown and Blakeley, 1983) milk. The EGF present in rat milk has been shown to be significant for the normal development of rat pups (Oka et al., 1983). EGF has not, however, been found in bovine milk (Read 1985). Instead, insulin-like growth factor (IGF) I and II (Francis et al., 1986) and bovine colostrum growth factor (BCGF), which is structurally related to Platelet-derived Growth Factor (PDGF) (Shing and Klagsbrun, 1984; Brown and Blakeley, 1994), have been identified in bovine milk
  • In published International Application WO 97/16460 it is disclosed that bovine milk contains growth promoting activity for a rat mammary fibroblast cell line (Rama 27), which is not significantly stimulated by IGF or PDGF. In this application peptide sequences are identified which elicit this growth promoting activity. These sequences are identified as sequences that are substantially identical to the C-terminal end of bovine α-S2 casein precursor. The application indicates that these peptides or salts thereof may be used for the manufacture of medicaments or foodstuffs for promoting growth.
  • Published European Patent Application EP 0 457 565 discloses milk protein hydrolysate and compositions for use in hair and skin treatment. The proteins in the hydrolysate are not specifically defined and have molecular weights of less than 1000 daltons. These are thus very small hydrolysis products from a wide variety of proteins present in milk
  • Published PCT Applications WO 92/00994, WO 95/29933 and WO 96/34614 disclose extracts from milk which may be used as growth promoting agents and agents for treating alimentary tract damage. The milk product extract may be from human or animal milk and includes cheese whey extracts and skim-milk extracts. The documents imply that IGF I or II are active ingredients giving the products their utility, and do not indicate that the products should comprise any specific protein.
  • In addition, topical applications, such as creams, have been marketed that claim anti-aging efficacy for added Epidermal Growth Factor (EGF) (Estee Lauder, advertised in Elle, 1999) and for ‘whey proteins’ (stee Lauder's ‘Diminish’ in Martha Stewart's Living, Feb, 2000). However, this efficacy has not been shown to be especially high.
  • In published international application WO 02/02133, a composition for treating periodontal disease and signs of aging in skin is disclosed. This composition employs an a-S2 casein precursor capable of stimulating the production of collagen in fibroblasts.
  • It is an object of the present invention to solve the problems associated with the prior art. In particular, it is an object of the present invention to provide an agent capable of alleviating or preventing the effects of aging in skin. It is also an object of the invention to provide an agent capable of treating or preventing periodontal disease. Surprisingly, the inventors have found that an α-S2 casein precursor and related species, such as those disclosed as growth promoters in WO 97/16460, are extremely useful in alleviating and preventing the effects of aging in skin, and in treating periodontal disease, by stimulating the production of fibrillin in fibroblasts. The α-S2 casein precursor and precursor fragments and derivatives used in the present invention are superior to known anti-aging products and products used for treating gum disease, and in particular to the agents disclosed in the above prior art.
  • Accordingly, the present invention provides use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full α-S2 casein precursor. The invention also provides use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide has an α-S2 casein fragment activity. The medicament is effective in alleviating or preventing periodontal disease and/or in alleviating or preventing an effect of aging in skin, preferably an effect of photoaging (damage or aging caused by exposure or overexposure to UV light or sunlight).
  • The above-defined uses of the present invention include use of the peptide, or its derivative, either in a pure form, or in a partially purified form, such as that obtainable by isolation of the peptide from a natural source. Thus, the present use may extend to employment of the peptide in its natural unpurified form, such as using a natural substance that comprises the peptide or its derivative, or may involve use of the peptide or its derivative in any level of purification, including entirely (100%) pure. The peptide may also be from a proteolytic digest or a non-natural source, such as a synthetic peptide. In the context of this invention, the term peptide is intended to include proteins, polypeptides and peptide fragments.
  • The present invention may be employed in a cosmetic and/or medicinal method for alleviating or preventing an effect of aging in skin, which method comprises treating a subject with a polypeptide, or a derivative of a polypeptide, wherein the polypeptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising the N-terminus of the full α-S2 casein precursor.
  • To reiterate, the present inventors have surprisingly found that a peptide comprising an amino acid sequence from an α-S2 casein precursor, and in particular a fragment of such a peptide, has a very beneficial effect upon the skin, preventing and alleviating many effects of aging, and treating and preventing periodontal disease. The effect of these particular agents is superior to the effect of prior art agents. By fragments, in the context of the present invention it is meant any part of a sequence from a protein, polypeptide or peptide that is not the full sequence.
  • The invention will be further described by way of example only with reference to the following drawings and specific embodiments, in which:
  • FIG. 1 shows the result of a cation exchange column chromatography experiment carried out on a dialysed cheese whey salt-cut;
  • FIG. 2 shows the results of a hydrophobic interaction column chromatography experiment performed on active fractions from cation exchange chromatography,
  • FIG. 3 shows fibrillin production in ten human volunteers treated with peptides of the present invention, compared with occluded controls; and
  • FIG. 4 shows a corresponding pooled analysis of this study.
  • In the context of the present invention, the effect of aging may be any effect of aging. Thus the effect may be sagging of the skin, wrinkling of the skin or slow regeneration of damaged areas of skin. However, the effect is most preferably wrinkling of the skin. The periodontal disease is a disease of the gums. In the context of the present invention, this may be a gum disease arising for any reason, including infection of the teeth or gums as well as lack of cleaning (brushing or flossing) of the teeth or gums.
  • The polypeptide and polypeptide fragments used in the present invention may have either an alleviating effect, or a preventative effect, or both. Thus, they may have a prophylactic effect and/or may reduce the effects of gum disease or of aging, or provide protection against the onset of gum disease or may increase the youthful appearance of the skin.
  • Whilst the whole α-S2 casein precursor shows no significant efficacy against the effects of aging or gum disease, fragments of such proteins, such as polypeptides derived from the C-terminal end of α-S2 caseins, do have these effects. For example, the efficacy against gum disease and effects of aging is present in peptides which are derived from the C-terminal end of α-S2 casein precursors and have 3 or more amino acids, but do not comprise the N-terminal amino acid of the full α-S2 casein molecule. Thus, the casein-derived peptides and fragments used in the present invention generally comprise 3 or more amino acids and do not comprise the N-terminus of the full casein protein. In the context of the present invention, the peptide not comprising the N-terminal amino acid means that the peptide does not comprise the N-terminal end (N-terminus) of the protein itself. In some embodiments this can mean that the peptide does not comprise a number of amino acids up to and including the N-terminus. Preferably the peptides do comprise the C-terminus of the-full protein.
  • Thus, the number of amino acids in the peptide or fragment used the present invention is not especially limited, provided that it has 3 or more amino acids, but does not comprise the N-terminal end of the full casein. However, it is preferred that the number of amino acids in the peptide is from 3-50, 4-50, 5-50, 6-50, or 7-50. Advantageously, the number of amino acids may be from 8-50 and more preferably from 9-50 or 10-50. It is particularly preferred that the upper limit on the amino acids in all these cases is 35 and most preferably 31. The most preferred number of amino acids is from 9-31.
  • Thus, the peptide may preferably comprise the last 3-50, 3-35 or 3-31 amino acids of the C-terminal end of the α-S2 casein precursor (including the C-terminus) and may even be as short as the last 3-10, 3-9,3-8 or 3-7 or even just the last 3 amino acids of the C-terminal end of the α-S2 casein.
  • The bovine α-S2 casein precursor used in the present invention has the following amino acid sequence:
    • [CAS2_BOVIN] ALPHA-S2 CASEIN PRECURSOR
  • SEQUENCE:
    MKFFIFTCLL AVALAKNTME HVSSSEESII SQETYKQEKN MAINPSKENL CSTFCKEVVR
    NANEEBYSIG SSSEESAEVA TEEVKITVDD KHYQKALNEI NQFYQKFPQY LQYLYQGPIV
    LNPWDQVKRN AVPITPTLNR EQLSTSEENS KKTVDMESTE VFTKKTKLTE EEKNRLNFLK
    KISQRYQKFA LPQYLKTVYQ HQKAMKLPWIQ PKTKVIPYVR YL
  • In three letter codes this translates to:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys Asn Thr Met Glu
    His Val Ser Ser Ser Glu Glu Ser Ile Ile
    Ser Gln Glu Thr Tyr Lys Gln Glu Lys Asn
    Met Ala Ile Asn Pro Ser Lys Glu Asn Leu
    Cys Ser Thr Phe Cys Lys Glu Val Val Arg
    Asn Ala Asn Glu Glu Glu Tyr Ser Ile Gly
    Ser Ser Ser Glu Glu Ser Ala Glu Val Ala
    Thr Glu Glu Val Lys Ile Thr Val Asp Asp
    Lys His Tyr Gln Lys Ala Leu Asn Glu Ile
    Asn Gln Phe Tyr Gln Lys Phe Pro Gln Tyr
    Leu Gln Tyr Leu Tyr Gln Gly Pro Ile Val
    Leu Asn Pro Trp Asp Gln Val Lys Arg Asn
    Ala Val Pro Ile Thr Pro Thr Leu Asn Arg
    Glu Gln Leu Ser Thr Ser Glu Glu Asn Ser
    Lys Lys Thr Val Asp Met Glu Ser Thr Glu
    Val Phe Thr Lys Lys Thr Lys Leu Thr Glu
    Glu Glu Lys Asn Arg Leu Asn Phe Leu Lys
    Lys Ile Ser Gln Arg Tyr Gln Lys Phe Ala
    Leu Pro Gln Tyr Leu Lys Thr Val Tyr Gln
    His Gln Lys Ala Met Lys Pro Trp Ile Gln
    Pro Lys Thr Lys Val Ile Pro Tyr Val Arg
    Tyr Leu
  • It is preferred in the present invention that the peptide comprises an amino acid sequence selected from the following sequences:
    LysValIleProTyrValArgTyrLeu;
    ThrLysValIleProTyrValArgTyrLeu;
    LysThrLysValIleProTyrValArgTyrLeu;
    ProLysThrLysValIleProTyrValArgTyrLeu;
    GlnProLysThrLysValIleProTyrValArgTyrLeu;
    AlaMetLysProTrpIleGlnProLysThrLysValIleProTyrVal
    ArgTyrLeu;
    ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys
    ThrLysValIleProTyrValArgTyrLeu;
    and
    ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysPro
    TrpIleGlnProLysThrLysValIleProTyrValArgTyrLeu.
  • These sequences all comprise the last 9 amino acids of the C-terminal end of the bovine α-S2 casein precursor. The present inventors have found that peptide sequences incorporating this C-terminal sequence, LysValIleProTyrVaLrgTyrLeu, show particularly marked anti-aging activity. Thus in a particularly preferred aspect of the present invention the polypeptide comprises a bovine α-S2 casein fragment comprising the sequence LysValIleProTyrValArgTyrLeu. Other particularly preferred sequences referred to above include the last 10, 11, 12 and 13 amino acids of the C-terminal end of the bovine α-S2 casein precursor. These amino acids are also the same as the last 7 amino acids of the goat and sheep α-S2 casein precursors, confirming the degree of similarity between these proteins, particularly at their C-termini
  • It is also preferred in the present invention that the peptide comprises an amino acid sequence from the C-terminal end of the bovine α-S2 casein precursor, but without the last four C-terminal amino acids (i.e. without ValArgTyrLeu). Thus, the following sequences are also preferred:
    LysValIleProTyr;
    ThrLysValIleProTyr;
    LysThrLysValIleProTyr;
    ProLysThrLysValIleProTyr;
    GlnProLysThrLysValIleProTyr;
    AlaMetLysProTrpIleGlnProLysThrLysValIleProTyr;
    ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys
    ThrLysValIleProTyr;
    and
    ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysPro
    TrpIleGlnProLysThrLysValIleProTyr.
  • As highlighted above, there is a high degree of homology between the C-terminal end sequence of α-S2 casein precursors of bovine, goat, sheep, rabbit and pig origin. It is apparent from the sequences of these caseins that the C-terminal sequence can vary from species to species, but that there are important similarities. Accordingly, whilst bovine α-S2 casein precursor fragments are preferred for use in the present invention, goat, sheep, rabbit and-pig α-S2 casein fragments, or similar fragments from other species, may also be employed if desired.
  • The sequences for α-S2 casein precursors of goat, sheep, rabbit and pig origin are set out below.
    • [CAS2 CAPH1] α-S2 casein precursor (α-S2-CN)
  • SEQUENCE:
    MKFFIFTCLL AVALAKHKME HVSSSEEPIN IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV
    RNANEEEYSI RSSSEESAEV APEEIKITVD DKHYQKALNE INQFYQKFPQ YLQYPYQGPI
    VLNPWDQVKR NAGPFTPTVN REQLSTSEEN SKKTIDMEST EVFTKKTKLT EEEKNRLNFL
    KKISQYYQKF AWPQYLKTVD QHQKAMKPWT QPKTNAIPYV RYL        223
    • >pir|S33881|S33881 α-S2 casein E—goat
  • SEQUENCE:
    MKFFIFTCLL AVALAKHKME HVSSSEEPIN IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV
    RNANEEEYSI RSSSEESAKV APEEIKITVD DKHYQKALNE INQFYQKFPQ YLQYPYQGPI
    VLNPWDQVKR NAGPFTPTVN REQLSTSEEN SKKTIDMEST EVFTKKTKLT EEEKNRLNFL
    KKISQYYQKF AWPQYLKTVD QHQKAMKPWT QPKTNAIPYV RYL        223
    • α-S2 casein C—capra hircus
  • SEQUENCE:
    MKFFIFTCLL AVALAKHKME HVSSSEEPIN IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV
    RNANEEEYSI RSSSEESAEV APEEIKITVD DKHYQKALNE INQFYQKFPQ YLQYPYQGPI
    VLNPWDQVKR NAGPFTPTVN REQLSTSEEN SKKTIDMEST EVFTKKTKLT EEEKNRLNFL
    KKISQYYQKF AWPQYLKTVD QHQKAMKPWT QPKTNAIPYV RYL        223
    • >pir|S39776|S39776 α-S2 casein form b precursor—rabbit
    • >gp|X76909|OCPAS2BCS —1 pre-α-S2b casein (AA-15 to 167) Oryctglagus cuniculus
  • SEQUENCE:
    MKFFIFTCLL AVALAKPKIE QSSEETIAV SQEVSPNLEN ICSTACEEPI KNINEVEYVE
    VPTEIKDQEF YQKVNLLQYL QALYQYPTVM DPWTRAETKA IPFIRTMQYK QEKDATKHTS
    QKTELTEEEK AFLKYLDEMK QYYQKFVFPQ YLKNAHHFQK TMNPWNHVKT IIYQVPTSL 179
    • [CAS2_SHEEP] α-S2 casein precursor—sheep
  • SEQUENCE:
    MKFFIFTCLL AVALAKHKME HVSSSEEPIN ISQEIYKQEK NMAIHPRKEK LCTTSCEEVV
    RNADEEEYSI RSSSEESAEV APEEVKITVD DKHYQKALNE INQFYQKFPQ YLQYLYQGPI
    VLNPWDQVKR NAGPFTPTVN REQLSTSEEN SKKTIDMEST EVFTKKTKLT EEEKNRLNFL
    KKISQYYQKF AWPQYLKTVD QHQKAMKPWT QPKTNAIPYV RYL        223
    • [CAS2_PIG] α-S2 casein precursor—pig
  • SEQUENCE:
    MKFFIFTCLL AVAFAKHEME HVSSSEESIN ISQEKYKQEK NVINHPSKED ICATSCEEAV
    RNIKEVGYAS SSSSEESVDI PAENVKVTVE DKHYLKQLEK ISQFYQKFPQ YLQALYQAQI
    VMNPWDQTKT SAYPFIPTVI QSGEELSTSE EPVSSSQEEN TKTVDESME  EFTKKTELTE
    EEKNRIKFLN KIKQYYQKFT WFQYIKTVHQ KQKAMKPWNH IKTNSYQIIP NLRYF  235
  • In three letter codes, these sequences translate to the following.
    • [CAS2 CAPH1] α-S2 casein precursor (α-S2-CN)
  • SEQUENCE:
    Met Lys Phe Iie Phe Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys His Lys Met Glu
    His Val Ser Ser Ser Gly Gly Pro Ile Asn
    Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys
    Asn Met Ala Ile His Pro Arg Lys Glu Lys
    Leu Cys Thr Thr Ser Cys Glu Glu Val Val
    Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile
    Arg Ser Ser Ser Glu Glu Ser Ala Glu Val
    Ala Pro Glu Glu Ile Lys Ile Thr Val Asp
    Asp Lys His Tyr Gln Lys Ala Leu Asn Glu
    Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln
    Tyr Leu Gln Tyr Pro Tyr Gln Gly Pro Ile
    Val Leu Asn Pro Trp Asp Gln Val Lys Arg
    Asn Ala Gly Pro Phe Thr Pro Thr Val Asn
    Arg Gln Gln Leu Ser Thr Ser Glu Glu Asn
    Ser Lys Lys Thr Ile Asp Met Gln Ser Thr
    Glu Val Phe Thr Lys Lys Thr Lys Leu Thr
    Gln Gln Glu Lys Asn Arg Leu Asn Phe Leu
    Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe
    Ala Trp Pro Gln Tyr Len Lys Thr Val Asp
    Gln His Gln Lys Ala Met Lys Pro Trp Thr
    Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
    Arg Tyr Leu
    • pir|S33881|S33881 α-S2 casein E—goat
  • SEQUENCE:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys His Lys Met Glu
    His Val Ser Ser Ser Glu Glu Pro Ile Asn
    Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys
    Asn Met Ala Ile His Pro Arg Lys Glu Lys
    Leu Cys Thr Thr Ser Cys Glu Glu Val Val
    Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile
    Arg Ser Ser Ser Glu Glu Ser Ala Lys Val
    Ala Pro Glu Glu Ile Lys Ile Thr Val Asp
    Asp Lys His Tyr Gln Lys Ala Leu Asn Glu
    Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln
    Tyr Leu Gln Tyr Pro Tyr Gln Gly Pro Ile
    Val Leu Asn Pro Trp Asp Gln Val Lys Arg
    Asn Ala Gly Pro Phe Thr Pro Thr Val Asn
    Arg Glu Gln Leu Ser Thr Ser Glu Glu Asn
    Ser Lys Lys Thr Ile Asp Met Glu Set Thr
    Glu Val Phe Thr Lys Lys Thr Lys Leu Thr
    Glu Glu Glu Lys Asn Arg Leu Asn Phe Leu
    Lys Lys Ile Set Gln Tyr Tyr Gln Lys Phe
    Ala Trp Pro Gln Tyr Leu Lys Thr Val Asp
    Gln His Gln Lys Ala Met Lys Pro Trp Thr
    Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
    Arg Tyr Leu
    • >gp|S74171|S74171 —1 α-S2 casein C—capra hircus
  • SEQUENCE:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys His Lys Met Glu
    His Val Ser Ser Ser Glu Glu Pro Ile Asn
    Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys
    Asn Met Ala Ile His Pro Arg Lys Glu Lys
    Leu Cys Thr Thr Ser Cys Glu Glu Val Val
    Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile
    Arg Ser Ser Ser Glu Glu Ser Ala Glu Val
    Asp Lys His Tyr Gln Lys Ala Leu Asn Glu
    Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln
    Tyr Leu Gln Tyr Pro Tyr Gln Gly Pro Ile
    Val Leu Asn Pro Trp Asp Gln Val Lys Arg
    Asn Ala Gly Pro Phe Thr Pro Thr Val Asn
    Arg Glu Gln Leu Ser Thr Set Glu Glu Asn
    Ser Lys Lys Thr Ile Asp Met Glu Ser Thr
    Glu Val Phe Thr Lys Lys Thr Lys Leu Thr
    Glu Glu Glu Lys Asn Arg Leu Asn Phe Leu
    Lys Ile Ile Ser Gln Tyr Tyr Gln Lys Phe
    Ala Trp Pro Gln Tyr Leu Lys Thr Val Asp
    Gln His Gln Lys Ala Met Lys Pro Trp Thr
    Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
    Arg Tyr Leu
    • >pir|S39776|S39776 α-S2 casein form b precursor—rabbit
    • >gp|X76909|OCPAS2BCS —1 pre-α-S2b casein (AA-15 to 167) Oryctolagus cuniculus
  • SEQUENCE:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys Pro Lys Ile Glu
    Gln Ser Ser Ser Glu Glu Thr Ile Ala Val
    Ser Gln Glu Val Ser Pro Asn Leu Glu Asn
    Ile Cys Ser Thr Ala Cys Glu Glu Pro Ile
    Lys Asn Ile Asn Glu Val Glu Tyr Val Glu
    Val Pro Thr Glu Ile Lys Asp Gln Glu Phe
    Tyr Gln Lys Val Asn Leu Leu Gln Tyr Leu
    Gln Ala Leu Tyr Gln Tyr Pro Thr Val Met
    Asp Pro Trp Thr Arg Ala Glu Thr Lys Ala
    Ile Pro Phe Ile Arg Thr Met Gln Tyr Lys
    Gln Glu Lys Asp Ala Thr Lys His Thr Ser
    Gln Lys Thr Glu Leu Thr Glu Glu Glu Lys
    Ala Phe Leu Lys Tyr Leu Asp Glu Met Lys
    Gln Tyr Tyr Gln Lys Phe Val Phe Pro Gln
    Tyr Leu Lys Asn Ala His His Phe Gln Lys
    Thr Met Asn Pro Trp Asn His Val Lys Thr
    Ile Ile Tyr Gln Set Val Pro Thr Leu
    • [CAS2_SHEEP] α-S2 casein precursor—sheep
  • SEQUENCE:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Leu Ala Lys His Lys Met Glu
    His Val Ser Ser Ser Glu Glu Pro Ile Asn
    Ile Ser Gln Glu Ile Tyr Lys Gln Glu Lys
    Asn Met Ala Ile His Pro Arg Lys Glu Lys
    Leu Cys Thr Thr Ser Cys Glu Glu Val Val
    Arg Asn Ala Asp Glu Glu Glu Tyr Ser Ile
    Arg Ser Ser Ser Glu Glu Ser Ala Glu Val
    Ala Pro Glu Glu Val Lys Ile Thr Val Asp
    Asp Lys His Tyr Gln Lys Ala Leu Asn Glu
    Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln
    Tyr Leu Gln Tyr Leu Tyr Gln Gly Pro Ile
    Val Leu Asn Pro Trp Asp Gln Val Lys Arg
    Asn Ala Gly Pro Phe Thr Pro Thr Val Asn
    Arg Glu Gln Leu Ser Thr Ser Glu Glu Asn
    Ser Lys Lys Thr Ile Asp Met Glu Ser Thr
    Glu Val Phe Thr Lys Lys Thr Lys Leu Thr
    Glu Glu Glu Lys Asn Arg Leu Asn Phe Leu
    Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe
    Ala Trp Pro Gln Tyr Leu Lys Thr Val Asp
    Gln His Gln Lys Ala Met Lys Pro Trp Thr
    Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
    Arg Tyr Leu
    • [CAS2 PIG] α-S2 casein precursor—pig
  • SEQUENCE:
    Met Lys Phe Phe Ile Phe Thr Cys Leu Leu
    Ala Val Ala Phe Ala Lys His Glu Met Glu
    His Val Ser Ser Ser Glu Glu Ser Ile Asp
    Ile Ser Gln Glu Lys Tyr Lys Gln Glu Lys
    Asn Val Ile Asn His Pro Ser Lys Glu Asp
    Ile Cys Ala Thr Ser Cys Glu Glu Ala Val
    Arg Asn Ile Lys Glu Val Glu Tyr Ala Ser
    Ser Ser Ser Ser Glu Glu Ser Val Asp Ile
    Pro Ala Glu Asn Val Lys Val Thr Val Glu
    Asp Lys His Tyr Leu Lys Gln Leu Glu Lys
    Ile Ser Gln Phe Tyr Gln Lys Phe Pro Gln
    Tyr Leu Gln Ala Leu Tyr Gln Ala Gln Ile
    Val Met Asn Pro Trp Asp Gln Thr Lys Thr
    Ser Ala Tyr Pro Phe Ile Pro Thr Val Ile
    Gln Ser Gly Glu Glu Leu Ser Thr Ser Glu
    Glu Pro Val Ser Ser Ser Gln Glu Glu Asn
    Thr Lys Thr Val Asp Met Glu Ser Met Glu
    Glu Phe Thr Lys Lys Thr Glu Leu Thr Glu
    Glu Glu Lys Asn Arg Ile Lys Phe Leu Asn
    Lys Ile Lys Gln Tyr Tyr Gln Lys Phe Thr
    Trp Pro Gln Tyr Ile Lys Thr Val His Gln
    Lys Gln Lys Ala Met Lys Pro Trp Asn His
    Ile Lys Thr Asn Ser Tyr Gln Ile Ile Pro
    Asn Leu Arg Tyr Phe
  • Furthermore, due to the similar nature of some amino acids it is possible to interchange some amino acids without affecting the functioning of the sequence. Accordingly leucine, isoleucine and valine may be interchanged. In addition tyrosine and phenylalanine may also be interchanged, as may arginine and lysine.
  • The invention will now be discussed in more detail. The invention preferably relates to α-S2 casein precursor fragments, and more preferably to the peptides referred to in WO 97/16460, for use as a cosmetic product, preferably in a cream or lotion, for reducing an aging effect in skin, such as wrinkles. The invention is preferably applicable to human skin, but may if desired be applied to other skin such as mammalian skin generally.
  • The invention also relates to the α-S2 casein precursor fragments mentioned above for use as a prophylactic agent or treatment agent for periodontal disease. This preferably relates to such diseases in humans, but may also apply to such diseases in mammalian gums generally if desired. The agent may be in any suitable form, such as a topical agent (e.g. a toothpaste for cleaning the teeth and/or gums) or a chewing gum.
  • The peptides may be used as a pure product, or may conveniently be supplied as an enriched natural preparation from milk by following the protocols described in WO 97/16460 as far as (and including) the hydrophobic interaction chromatography step. Alternatively, cheese whey may be used in place of the acid (milk) whey.
  • The peptides may be used alone, or in combination with acceptable (in some cases pharmaceutically acceptable) additives and/or excipients useful for formulating topical compositions, toothpastes, or chewing gums. Additives for topical agents may include, for example, moisturising agents and/or other agents beneficial to the skin, such as all or any of vitamins A, C, D and E, that are used to beneficial effect to prevent/reverse the aging of skin.
  • Without being bound by theory, it is believed that the basis of the invention is that the peptides stimulate the production of fibrillin in fibroblasts, especially dermal fibroblasts. This is believed to ameliorate the fibrillin-rich microfibrillar network proximal to the dermal-epidermal junction of aged skin. Thus the peptides are capable of repairing the fibrillin deficit in aged (especially photoaged) skin.
  • The peptides used in the present invention appear to fulfil the equivalent role in bovine milk that EGF does in other species. The present inventors have surprisingly discovered that these peptides are effective as anti-periodontal disease agents and anti-aging agents and are more effective than known products. A further advantage of the peptides used in the present invention is that whilst they have an efficacy similar to, or are superior to, EGF they are regarded as being ‘natural products’ (being milk-derived) and because they have essentially no full protein content, they are not allergenic.
  • In the present invention the peptide, or derivative of the peptide, can be used in the manufacture of a medicament effective in alleviating or preventing an effect of aging in ski, wherein the peptide has an α-S2 casein fragment activity. Thus the peptide may be an α-S2 casein precursor fragment, as described in detail above, or ca be a related molecule having a similar activity, such as a homologue. The peptides are particularly effective against photoaging. In the present context, photoaging of skin means the effects of cumulative exposure to ultra-violet radiation and/or sunlight, or alternatively the combination of chronological ageing and the effects of cumulative exposure to ultra-violet radiation and/or sunlight. Typically, it is manifested clinically by coarse and fine wrinkling, dyspigmentation, sallowness and the formation of benign and malignant neoplasms. The mechanisms of wrinkle formation are not fully understood, but without being bound by theory, it is thought that the glycoprotein fibrillin may be important. Fibrillin is a major constituent of the elastin network in the papillary dermis and plays an important role in maintaining the integrity of the basement membrane zone. The present invention relates to methods of repairing the basement membrane zone, by stimulating the production of fibrillin.
  • Also in the present invention, the peptide, or derivative of the peptide, can be used in the manufacture of a medicament effective in alleviating or preventing periodontal disease, wherein the peptide has an α-S2 casein fragment activity. Thus, as in the related aspect, the peptide may be an α-S2 casein precursor fragment, as described in detail above, or can be a related molecule having a similar activity, such as a homologue.
  • Preferably the peptide used in the present invention is capable of stimulating the growth of fibroblasts. It is also preferred that the peptide is capable of stimulating fibroblasts to produce collagen. It is further preferred that the peptide is capable of stimulating growth in keratinocytes.
  • In a further aspect, the present invention provides a cosmetic method, or a medical method, for alleviating or preventing an effect of aging in skin by stimulating the production of fibrillin in fibroblasts, which method comprises treating a subject with a peptide, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full α-S2 casein precursor. The peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an α-S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • In a still further aspect, the present invention provides a topical composition for stimulating the production of fibrillin by fibroblasts, comprising a peptide, or a derivative of a peptide, wherein the peptide comprises an amino acid sequence present in an x-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full α-S2 casein precursor. The peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an α-S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • In a related aspect, the invention provides a pharmaceutical composition for alleviating or preventing periodontal disease by stimulating the production of fibrillin by fibroblasts, comprising a peptide, or a derivative of a peptide, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full α-S2 casein precursor. Again, the peptide is preferably a specific peptide as discussed in detail above, but alternatively may be an α-S2 casein precursor fragment, or a related molecule having a similar activity, such as a homologue.
  • The invention will be further described by way of example only with reference to the following specific embodiments.
    • EXAMPLES Example 1 Preparation of Standardised Natural Product from Cheese Whey
  • This procedure covers the methods for the collection, preparation and storage of Standardised Natural Product (SNP) from cheese whey. Typically, this procedure is used for small-scale preparation of SNP, such as for research and development purposes. However, the procedure can be scaled up as desired for commercial production according to known techniques.
  • Collection and Storage of Cheese Whey
  • Approximately 401 of fresh clarified cheese whey was obtained from DewLay cheese manufacturing plant (Garstang, Lancashire). The whey was collected in clean containers and immediately transported to Pepsyn Central Manufacturing Facility (Liverpool).
  • Whey was either refrigerated for processing the following day or the whey was frozen at −20° C. in shallow 21 containers until required.
  • Thawing of Cheese Whey
  • Frozen whey was thawed by placing a 2 l block of whey in a plastic bag and immersing it in hot running water. Thawing was completed in less than 10 mins and the temperature of the melting whey was maintained below 10° C.
  • Salting Out
  • The pH of the whey was adjusted to 3.0 using concentrated HCl. To each litre of whey, 220 g of (NH4)2SO4 (BDH, AnalaR grade) was slowly added over a period of 30 mins whilst stirring. It was left to equilibrate for a further 1 hr 30 mins without stirring, and then centrifuged at 9000 rpm for 40 mins using a SorvallRC-5B centrifuge and associated GS-3 rotor (DuPont Instruments), which were pre-equilibrated to an operating temperature of between 4 and 10° C. To each litre of supernatant recovered, 130 g of (NH4)2SO4 was added, and left to equilibrate and centrifuged as described above. The supernatant was discarded and the pellet was redissolved in distilled water (400 ml for each litre of whey started with). This was dialysed with visking tubing MWCO 12,000 to 14,000 daltons (Medicell Int. Ltd, UK) against running tap water overnight and then with 20 mM sodium phosphate buffer at pH 6.0 for 7 hr with one change of buffer. The dialysed salt-cut was collected and either refrigerated for processing the following day or frozen (−20° C.) until required.
  • Cation Exchange Chromatography
  • Dialysed cheese whey salt-cut was run on cation-exchange chromatography, at 4° C. with a mobile phase of 20 mM sodium phosphate buffer, pH 6.0. Protein was eluted using a linear salt gradient of 100 to 700 mM NaCl provided by a gradient mixer (Pharmacia gradient mixer GM-1). The progress of the run was monitored at 280 nm using a UV monitor (Uvicord S II, Pharmacia).
  • A cation exchange column (Pharmacia XK50series, 50 mm i.d.) was prepared with CM52 carboxymethyl (Whatman) to a packed bed height of 15 cm. This was equilibrated with 500 ml of buffer solution. Dialysed cheese whey salt cut (400 ml) was loaded on the column at a flow rate of 2.5 ml/min and then washed overnight with 500 ml of 50 mM NaCl in buffer at a flow rate of about 0.5 ml/min. A 500 ml linear gradient of 100 to 700 mM NaCl in buffer was applied at a 2.0 ml/min and fractions were collected every 25 ml and numbered sequentially. The column was then washed with 300 ml of 2M NaCl in buffer. Collected fractions were tested for growth promoting activity. This was typically observed in fraction numbers 11 and 12 that contained lactoferrin, and also in the fractions just before and after these (see FIG. 1). Because lactoferrin gave a brown appearance to the fractions then this was used as a visual marker for activity. The mean estimated concentration of NaCl in each of the collected fractions is given in Table 1. All fractions were frozen until required for the next chromatographic step.
    TABLE 1
    Concentration of NaCl in each fraction from CM52 run.
    Fraction Estimated NaCl (mM)
    5 115
    6 145
    7 175
    8 205
    9 235
    10 265
    11 295
    12 325
    13 355
    14 385
    15 415
    16 445
    17 475
    18 505
    19 535
    20 565
    21 595
    22 625
    23 655
    24 685

    N.B. Between the column inlet and outlet there was approximately 100 ml excluded volume. Therefore fraction 1 to 4 contained 50 mM NaCl from the wash buffer.

    Hydrophobic Interaction Chromatography
  • Active fractions from cation exchange chromatography were run on hydrophobic interaction chromatography (HIC). This was performed at room temperature with a mobile phase of 20 mM sodium phosphate buffer at pH 6.5. Protein was eluted using a linear salt gradient of 4 to 0 M NaCl provided by a gradient mixer (Pharmacia gradient mixer GM-1). The progress of the run was monitored at 280 nm using a UV monitor (Uvicord S II, Pharmacia).
  • A HIC column (Pharmacia C series, 26 mm i.d.) was prepared with Butyl Sepharose 4 Fast Flow (Pharmacia) to give a packed bed height of 15 cm. The column was equilibrated overnight with 250 ml of 4 M NaCl in buffer at a flow rate of 0.25 ml/min.
  • The active fractions from several cation exchange chromatography runs were pooled together to give between 100 and 200 ml of sample. The means concentration of NaCl in this sample was calculated from the estimated concentrations of NaCl in the constituent fractions (Table 1). Solid NaCl was then slowly added to the sample to make it 3.7 M, and the pH was adjusted to 6.5. Sample was loaded on the column added to 2.0 ml/min. A 500 ml eluting gradient of 4 M to 0 M NaCl was applied and fractions were collected every 25 ml and numbered sequentially. The column was then washed with 250 ml of buffer followed by 250 ml of water.
  • Collected fractions were tested for growth promoting activity. This was typically observed in fraction numbers 10 to 13, which were the fractions that eluted just before the brown lactoferrin fractions (see FIG. 2). Active fractions were pooled, extensively dialysed against distilled water and freeze-dried.
    • Example 2 Demonstration that SNP Increases Fibrillin Synthesis In Vivo in Humans
  • This Example shows that the peptides employed in the present invention stimulate the replacement of fibrillin in vivo, aiding in the repair of skin that has been photoaged. The peptides thus have clinical efficacy.
  • The study involves a topical application of casein peptides (36 μg SNP/ml of water; SNP was produced in accordance with Example 1) to determine the change in the expression of fibrillin and pro-collagen I in photoaged skin. Occlusion-only controls were also studied.
  • Patch-Test Control
  • Ten healthy, but photoaged, volunteers were recruited (male: 7; female: 3; age range 37-77 years). Test substances were applied separately under standard 6 mm diameter Finn chambers to the extensor aspect of the forearm; these were casein peptides (36 μg SNP/ml water), and occluded baseline control. After treatment for 4 days the Finn chambers were removed, and a 3 mm punch biopsy was be obtained under 1 vol. % lignocaine anaesthesia from each test site. Each biopsy was snap frozen in liquid nitrogen and processed histological assessment. Biopsy sites were sutured with 1×4/o ethilon and subjects instructed to return in 74 days for suture removal.
  • Fibrillin Examination by Immunohistochemistry
  • Frozen sections were prepared at a thickness of 10 μm (OTF cryostat, Bright Instruments Ltd.). Three sections per area per patient were treated as follows to identify the fibrillin-rich microfibrillar network by light microscopy:
  • Sections were fixed with 4 vol. % paraformaldehyde in phosphate-buffered saline (10 mins). Following hydration in tris-buffered saline (TBS; 100 mM Tris, 150 mM NaCl), sections were solubilised by addition of 0.5 vol. % Triton-X 100® (10 mins). Following washing, endogenous peroxidase activity was abolished by incubation with an excess of hydrogen peroxide in methanol (30 mins). All sections were then blocked with 1 vol. % normal horse serum+1 vol. % bovine serum albumen, prior to application of primary antibody (mouse anti-human fibrillin-1, clone 11C1.3; NeoMarkers, Calif., USA) at a dilution of 1:100. Negative controls were concurrently incubated with either block alone or control mouse serum at a dilution of 1:100. Following incubation, sections were stringently washed with TBS prior to application of the horse anti-mouse IgG biotinylated secondary antibody. This was further conjugated to the enzyme horseradish peroxidase using a commercially available kit following the manufacturers instructions (ABC Elite System, Vector Laboratory, Peterborough UK). Antibody was localised using 3′,3′-diaminobenzadine as chromogen (10 mins incubation). Washing in TBS quenched this reaction. Sections were counterstained using nuclear fast red and finally dehydrated through serial alcohols, cleared and permanently mounted.
  • Sections were randomised, blinded and examined on a Nikon OPTIPHOT microscope (Tokyo, Japan). The degree of immunostaining was assessed on a 5 point semi-quantitative scale where 0=no staining and 4=maximal sing. Four sections (including control) were examined per subject per site. The degree of immunostaining was scored for three high power fields per section, and the average score calculated for each site/test area.
  • Differences in the distribution of fibrillin protein between the test sites, and after application of test substances for varying periods of time, were assessed for significance using the analysis of variance test (ANOVA; SPSS+v10.0, SPSS Inc., IL USA).
  • The majority of volunteers tolerated the casein patch test protocol well; of the 10, only one individual complained of tenderness at the site of the casein application. The casein peptide patch produced deposition of fibrillin-1 proximal to the dermal/epidermal junction (base membrane zone) in 7/10 individuals (the volunteer who had complained of tenderness was amongst the 3 “non-responders” in this trial).
  • A known agent for stimulating fibrillin production is all-trans retinoic acid (RA). However, a drawback of this agent is that it produces marked erythema at the site of application. None of the above subjects produced erythema following application of casein, showing the advantage of this agent over all-trans retinoic acid.
  • Individual performance data is shown in FIG. 3. The mean data per volunteer was then pooled and is shown graphically in FIG. 4; all data is presented as means±SEM. In brief, it was found that casein had a very positive effect on the fibrillin-rich microfibrillar network of the papillary dermis over that of baseline (occluded: 0.93=0.21; casein: 1.86=0.39; p=0.023).
  • From this Example it can be seen that topical application of casein peptides (under occlusion) ameliorates the fibrillin-rich microfibrillar network proximal to the dermal-epidermal junction of photoaged skin. These results show that casein peptides used in the present invention can repair the fibrillin deficit in photoaged skin and/or aged skin, and have clear clinical utility.
    • Example 3 Demonstration that SNP Increases Collagen Synthesis in Fibroblasts
  • Rama 27 rat mammary cells were grown to confluence, and their rate of synthesis of collagen was measured using the method of M. J. Warburton, S. A. Ferns, and P. S. Rudland, Experimental Cell Research, 137, 373-380 (1982). The rates of collagen synthesis as estimated by the incorporation of [3H]proline into hydroxyproline are set out in Table 2 below:
    TABLE 2
    Rates of collagen synthesis
    Concentration of SNP Cellular HO-proline Secreted HO-proline
    (mg/ml) (cpm) (cpm)
    0 53 54
    0.2 271 233
    0.4 232 327
    0.6 321 663
  • Adding up to 0.6 mg/ml of SNP gives rise to an approximate 12-fold increase in the secretion of collagen—from 54 cpm to 663 cpm. This also gives rise to an approximate doubling in the ratio of synthesised collagen that is secreted to that which is retained in the cell—from 54:53 (1:1) to 663:321 (2:1).
    • Example 4 Demonstration of the Effect of SNP on the Growth of Keratinocytes
  • Human keratinocytes (HatKat) were grown in keratinocyte growth medium (TCS Cellworks Ltd.) until 20% confluence. Then, in the same medium, the keratinocytes were grown for three days with 0.5% foetal calf serum (FCS), at which point the cells were counted in a Coulter® counter. The cell numbers obtained are set out in Table 3 below.
    TABLE 3
    Cell numbers
    Conditions of growth Number of cells
    Medium with 0.5% FCS 23,777
    Medium with 0.5% FCS + 10 ng/ml EGF 29,356
    Medium with 0.5% FCS + 0.6 mg/ml SNP 68,719
  • This shows that the presence of SNP gives rise to an approximate 3-fold increase in the growth of keratinocytes—from 23,777 to 68,719. This compares with a relatively modest increase with the use of 10 ng/ml EGF.
  • These results clearly demonstrate the collagen producing activity and growth promoting activity of the peptides used in the present invention.

Claims (20)

1. Use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its n-terminus the N-terminal amino acid of the full α-S2 casein precursor.
2. Use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide has an α-S2 casein fragment activity.
3. Use according to claim 1 or claim 2, wherein the medicament is effective in alleviating or preventing periodontal disease.
4. Use according to claim 1 or claim 2, wherein the medicament is effective in alleviating or preventing an effect of aging in skin.
5. Use according to any preceding claim, wherein the peptide comprises 9 or more amino acids.
6. Use according to any preceding claim, wherein the peptide comprises from 9-31 amino acids.
7. Use according to any preceding claim, wherein the peptide comprises the C-terminus of the full α-S2 casein precursor.
8. Use according to any preceding claim, wherein the peptide is derived from bovine, goat, sheep, rabbit or pig α-S2 casein or is a synthesized equivalent or homologue thereof.
9. Use according to any preceding claim, wherein the peptide comprises an amino acid sequence selected from the following sequences:
LysValIleProTyrValArgTyrLeu (SEQ. ID NO. 2);
ThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 3);
LysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 4);
ProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 5):
GlnProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 6:
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 7);
ThrValTyrGlnHisGlnLysAlaMetLysProTrplleGinProLysThrLysValIleProTyrValArgTyr Leu (SEQ. ID NO. 8); and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLysThrLysValIle ProTyrValArgTyrLeu (SEQ. ID NO. 9).
10. Use according to any of claims 1-9, wherein the peptide comprises an amino acid sequence selected from the following sequences:
LysValIleProTyr (SEQ. ID NO. 16);
ThrLysValIleProTyr (SEQ. ID NO. 17);
LysThrLysValIleProTyr (SEQ. ID NO. 18);
ProLysThrLysValIleProTyr (SEQ. ID NO. 19);
GlnProLysThrLysValIleProTyr (SEQ. ID NO. 20);
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyr (SEQ. ID NO. 21);
ThrValTyrGlnHisGInLysAlaMetLysProTrpIleGlnProLysThrLysValIleProTyr (SEQ. ID NO. 22); and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLysThrLysValIle ProTyr (SEQ. ID NO. 23).
11. Use according to any preceding claim, wherein the peptide comprises a peptide homologue in which:
(a) one or more of the amino acids Leu, Ile and Val are replaced by one another; and/or
(b) one or more of the amino acids Tyr and Phe are replaced by one another; and/or
(c) one or more of the amino acids Arg and Lys are replaced by one another.
12. Use according to any of claims 4-1, wherein the effect of aging is wrinkling of the skin.
13. Use according to any preceding claim, wherein the peptide is capable of stimulating the growth of fibroblasts.
14. Use according to any preceding claim, wherein the peptide is capable of stimulating fibroblasts to produce collagen.
15. Use according to any preceding claim, wherein the peptide is capable of stimulating the growth of keratinocytes.
16. Use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in repairing and/or maintaining the basement membrane zone of mammalian skin, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminus the N-terminal amino acid of the full α-S2 casein precursor.
17. Use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in repairing and/or maintaining the basement membrane zone of mammalian skin, wherein the peptide has an α-S2 casein fragment activity.
18. Use according to claim 16 or claim 17, wherein the medicament is effective in alleviating or preventing periodontal disease.
19. Use according to claim 16 or claim 17, wherein the medicament is effective in alleviating or preventing an effect of aging in skin.
20. Use according to any of claims 16-19, wherein the mammal is a human.
US10/512,512 2002-04-24 2003-04-02 Peptide composition Abandoned US20060019884A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/502,345 US7786081B2 (en) 2002-04-24 2006-08-09 Peptide composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0209384.7 2002-04-24
GBGB0209384.7A GB0209384D0 (en) 2002-04-24 2002-04-24 Peptide composition
PCT/GB2003/001439 WO2003091274A2 (en) 2002-04-24 2003-04-02 Use of alpha-s2 casein precursor-derived peptided

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/502,345 Continuation US7786081B2 (en) 2002-04-24 2006-08-09 Peptide composition

Publications (1)

Publication Number Publication Date
US20060019884A1 true US20060019884A1 (en) 2006-01-26

Family

ID=9935427

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/512,512 Abandoned US20060019884A1 (en) 2002-04-24 2003-04-02 Peptide composition
US11/502,345 Expired - Fee Related US7786081B2 (en) 2002-04-24 2006-08-09 Peptide composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/502,345 Expired - Fee Related US7786081B2 (en) 2002-04-24 2006-08-09 Peptide composition

Country Status (8)

Country Link
US (2) US20060019884A1 (en)
EP (1) EP1501538B1 (en)
JP (1) JP2005531539A (en)
AT (1) ATE446766T1 (en)
AU (1) AU2003222959A1 (en)
DE (1) DE60329838D1 (en)
GB (1) GB0209384D0 (en)
WO (1) WO2003091274A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092431A1 (en) * 2008-12-15 2011-04-21 Calpis Co., Ltd. Skin aging-inhibiting peptide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209384D0 (en) 2002-04-24 2002-06-05 Pepsyn Ltd Peptide composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427769A (en) * 1992-12-28 1995-06-27 Nestec S.A. Prevention of dental caries

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558770A (en) * 1967-09-01 1971-01-26 Kraftco Corp Wound treating composition employing an enzyme modified casein
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
JPH03255095A (en) 1990-03-02 1991-11-13 Kanebo Ltd Casein peptide
EP0457565B1 (en) 1990-05-18 1997-07-30 Morinaga Milk Industry Co., Ltd. Milk-protein hydrolyzates and compositions for use as hair and skin treating agent
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DK0545946T3 (en) 1990-07-13 2005-05-23 Gropep Ltd Growth promoter
FR2673374A1 (en) 1991-03-01 1992-09-04 Oreal COSMETIC COMPOSITION CONTAINING AS ACTIVE INGREDIENT A PEPTIDE WITH OPIOUID ACTIVITY.
JPH06211689A (en) 1993-01-19 1994-08-02 Kanebo Ltd Sedative and ataractic food
US5965536A (en) * 1993-12-15 1999-10-12 Board Of Regents, The University Of Texas System Methods of inhibiting CXC intercrine molecules
AUPM534794A0 (en) 1994-04-28 1994-05-19 Gropep Pty Ltd Modified milk growth factor
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
GB9522302D0 (en) * 1995-10-31 1996-01-03 Univ Liverpool Growth promoters
JP2001525853A (en) 1997-05-19 2001-12-11 コルゲート・パーモリブ・カンパニー Remineralization of teeth without fluoride
JP3255095B2 (en) 1997-09-30 2002-02-12 日本電気株式会社 Polishing liquid and polishing method
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
CA2296311A1 (en) * 1999-01-28 2000-07-28 Universite Laval Enzymatic hydrolysate of milk proteins
GB0016189D0 (en) * 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
GB0209384D0 (en) 2002-04-24 2002-06-05 Pepsyn Ltd Peptide composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427769A (en) * 1992-12-28 1995-06-27 Nestec S.A. Prevention of dental caries

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092431A1 (en) * 2008-12-15 2011-04-21 Calpis Co., Ltd. Skin aging-inhibiting peptide
US9067972B2 (en) 2008-12-15 2015-06-30 Calpis Co., Ltd. Skin aging-inhibiting peptide

Also Published As

Publication number Publication date
US7786081B2 (en) 2010-08-31
AU2003222959A1 (en) 2003-11-10
WO2003091274A2 (en) 2003-11-06
EP1501538B1 (en) 2009-10-28
EP1501538A2 (en) 2005-02-02
ATE446766T1 (en) 2009-11-15
DE60329838D1 (en) 2009-12-10
AU2003222959A8 (en) 2003-11-10
JP2005531539A (en) 2005-10-20
WO2003091274A3 (en) 2003-12-24
US20070160558A1 (en) 2007-07-12
GB0209384D0 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
US5788967A (en) Composition and method for enhancing wound healing
US7579315B2 (en) Casein peptides for alleviating or preventing aging of skin
US7312193B2 (en) Calcium phosphopeptide complexes
TW503108B (en) Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US20030203008A1 (en) Preparation of collagen
AU2015202010B2 (en) Hatching fluid enzymes and uses thereof
KR20030009454A (en) SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1
AU2001264102A1 (en) Peptide composition for treatment of periodontal diseases and prevention of skin aging
CN109563132A (en) Skin regeneration or the peptide of Wound healing and bone regeneration and application thereof
JPS615006A (en) Agent for skin
WO2024078588A9 (en) New use of peptide compound in preparation of composition for skin aging repair
JP6259207B2 (en) Elastin production promoter
US8450456B2 (en) Activating peptide of the synthesis of aquaporins and cosmetic and/or pharmaceutical composition containing it
US7786081B2 (en) Peptide composition
WO2007002594A1 (en) Cosmetic compositions and methods using transforming growth factor-beta mimics
JP2002538212A (en) Matrix / protein composition for transplantation
KR102432887B1 (en) Skin health improvement set including skin cosmetics and edible film and skin care method using the same
HRP20040914A2 (en) Pharmaceutical and cosmetic compositions comprising plgf-1
KR20210039636A (en) Cosmetic composition for skin moisture and manufacturing method thereof
CN114929192B (en) Cosmetic preparation for topical application comprising novel peptides for improving skin appearance and regeneration
Yamani et al. Evaluation the Effect of Formulation made of Talh Honey, Whey Protein and Collagen on Acute Excisional Skin Wound Healing in Wistar Male Rat.
JPH0320206A (en) Skin cosmetic
KR20040056365A (en) A cosmetic composition comprising recombinant human Epidermal growth factor
AU746314B2 (en) Calcium phosphopeptide complexes
US20070275084A1 (en) Compositions And Methods For The Treatment Of Skin Damage

Legal Events

Date Code Title Description
AS Assignment

Owner name: PEPSYN LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SMITH, JOHN ARTHUR;REEL/FRAME:016454/0170

Effective date: 20050608

AS Assignment

Owner name: PEPSYN LTD., UNITED KINGDOM

Free format text: CHANGE OF ADDRESS;ASSIGNOR:PEPSYN LIMITED;REEL/FRAME:018274/0925

Effective date: 20060307

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载